2012 SABCS Public All Photos

225 / 280

San Antonio, TX - SABCS 2012 San Antonio Breast Cancer Symposium: A Goga discusses S3-8. Identification of novel synthetic-lethal targets for MYC-driven
triple-negative breast cancer during the General Session 3 at the 2012 San Antonio Breast Cancer Symposium here today, Thursday December 6, 2012. Over 9,000 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Date: Thursday December 6, 2012 Photo by © SABCS/Todd Buchanan 2012 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154.

A Goga

$San Antonio, TX - SABCS 2012 San Antonio Breast Cancer Symposium: JM Balko discusses S3-6. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease during the General Session 3 at the 2012 San Antonio Breast Cancer Symposium here today, Thursday December 6, 2012. Over 9,000 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Date: Thursday December 6, 2012 Photo by © SABCS/Todd Buchanan 2012 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154.$
$San Antonio, TX - SABCS 2012 San Antonio Breast Cancer Symposium: JM Balko discusses S3-6. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease during the General Session 3 at the 2012 San Antonio Breast Cancer Symposium here today, Thursday December 6, 2012. Over 9,000 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Date: Thursday December 6, 2012 Photo by © SABCS/Todd Buchanan 2012 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154.$
$San Antonio, TX - SABCS 2012 San Antonio Breast Cancer Symposium: JM Balko discusses S3-6. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease during the General Session 3 at the 2012 San Antonio Breast Cancer Symposium here today, Thursday December 6, 2012. Over 9,000 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Date: Thursday December 6, 2012 Photo by © SABCS/Todd Buchanan 2012 Technical Questions: todd@medmeetingimages.com; Phone: 612-226-5154.$